Effect of prostaglandin on estrus response and conception rate in lactating ongole cows

Aim: The present research work was carried to study the estrus response and conception rate in lactating Ongole cows consequence to double injection of prostaglandin. Material and Methods: Estrus synchronization was performed by double injection of PGF2α (Lutalyse, 5ml/cow) in purposively selected 22 lactating Ongole cows. The 1st injection was administered on 60 days post partum (day 0) followed by 2nd injection on 72 days postpartum (day 12) and then insemination was carried out at observed estrus. Results: The ovarian response by ultrasound scanning revealed a dominant follicle of 10.00 ± 0.78 mm 3-4 days after the PGF2α administration. Out of 22 cows treated with double injections of prostaglandins 18 cows exhibited estrus within 68.66 ± 10.24 hrs. The duration of estrus and mean estrous cycle length recorded as 14.20±2.56 hrs and 21.50±0.21 days, respectively. The estrous cycle was observed in 79.45 % cows. The remaining cows showed 11-17 (5.48%), 26-36 (9.59%) and 37- 60 (5.48 %) days of estrous cycle length. The conception rate of observed to be 67.00 ± 0.26 %. The mean calving to service period found to be 81.18±1.62 days in lactating multiparous Ongole cows. Conclusion: It may be concluded that double injection of Prostaglandin has reduced the calving to service period which would even truly reduce calving interval in lactating Ongole cows. [Vet World 2013; 6(7.000): 413-415

EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer

EGFR and c-Met are receptor tyrosine kinases that are implicated in tumor development and progression in several types of cancer. Both EGFR and c-Met, which are known to be overexpressed and mutated in cancer, share common signaling pathways, including the PI3K/ Akt and MAPK pathways. Small molecule tyrosine kinase inhibitors and monoclonal antibodies that work against EGFR and c-Met are at the forefront of cancer therapy, but their individual efficacies are limited due to the development of drug resistance. In recent pre-clinical studies, we observed that combination therapy using mTOR and Wnt inhibitors with EGFR or c-Met tyrosine kinase inhibitors resulted in overcoming drug resistance. Our studies also indicated that EGFR and c-Met tyrosine kinase inhibitor resistance may be due to activation of alternative signaling pathways. The development of additional combinatorial therapies is underway, and various combinations of inhibitors have shown promising results in clinical trials. Future studies in this direction could be the basis for development of new cancer therapeutics, utilizing EGFR and c-Met inhibitors, which could greatly improve patient prognosis